首页 > 市场调查报告书 > 製药

生物製剂分子标靶治疗学

市场调查报告书

商品编码

1289772

全球抗体药物结合物市场 - 2023-2030年

Global Antibody Drug Conjugates Market - 2023-2030

出版日期: 2023年06月12日 | 出版商:

DataM Intelligence | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概况

全球抗体药物结合物市场规模在2022年达到50.328亿美元，预计到2030年将出现有利可图的增长，达到165.946亿美元。在预测期间（2023-2030年），该市场的年复合增长率为16.6%。

全球抗体药物结合物市场的驱动因素包括：癌症发病率的增加，对癌症相关研究和开发的投资增加，癌症的创新和靶向治疗方案的增加，以及抗体工程和结合技术的进步。

市场动态

癌症发病率的增加

癌症发病率的增加是在预测期内推动市场份额的一个主要因素。全球癌症发病率的增加导致了更多的病人需要有效的治疗。ADCs通过直接向癌细胞传递细胞毒性载荷，提供了一种有针对性的癌症治疗方法，可能会改善治疗效果。随着癌症患者人数的增加，对ADC这样的创新和有效疗法的需求也越来越大。

传统的癌症治疗方法，如化疗、放疗和手术，在疗效和耐受性方面都有局限性。通过将单克隆抗体的特异性与化疗药物的细胞毒性作用相结合，ADCs已显示出更高的疗效。它们可以选择性地靶向癌细胞，而不伤害健康细胞，从而改善治疗效果。癌症发病率的增加使得开发和采用更有效的治疗方法成为必要，这使得ADCs成为一种有希望的解决方案。

ADCs的高生产成本和副作用

在预测期内，与抗体药物结合相关的高生产成本和副作用是阻碍市场份额的一个主要因素。ADC的开发和制造涉及复杂的过程，包括单克隆抗体的生产、共轭化学、纯化和配方。这些过程需要专门的基础设施、专业知识和资源，导致生产成本高。

生产ADC的高成本会限制它们的可及性和可负担性，特别是在预算有限的医疗系统或资源有限的地区。ADC的成本也可能成为医疗支付方报销的障碍，进一步影响市场份额。

ADC的设计是为了将细胞毒剂选择性地传递给癌细胞，但它们仍然可能引起脱靶效应和副作用。常见的副作用包括血液学毒性、肝脏毒性、免疫原性和输液相关反应。副作用和安全问题会影响患者对ADC的接受程度、治疗依从性和市场应用，因此减少副作用和提高安全性非常重要。

COVID-19影响分析

COVID-19大流行对抗体药物结合物市场产生了重大影响。该大流行病造成的全球供应链中断影响了ADC的生产和供应。封锁、旅行限制和检疫措施扰乱了物流和运输，导致原材料、试剂和成品的延误和短缺。供应链的中断已经影响了ADC的制造能力、库存水平和交付时间。

这场大流行还导致了ADC临床试验的延迟或暂停。医疗保健系统、临床试验主办方和监管机构的重点已转向解决大流行病，导致正在进行的临床试验的延迟和中断。延迟的临床试验会影响监管部门的批准时间和ADC的市场进入。

俄乌冲突分析

俄乌冲突对抗体药物结合市场产生了负面影响。如果冲突升级并导致政治不稳定，它可能会扰乱包括ADC在内的全球医药产品供应链。乌克兰是医药原料生产的重要参与者，拥有强大的制药业。

供应链的任何中断，如出口限制、运输中断或政治不稳定，都可能影响ADC生产所需原材料和成分的供应，有可能导致供应短缺并影响市场。

乌克兰和俄罗斯对国际癌症临床试验作出了重大贡献。乌克兰的局势将对进行临床试验产生各种影响，但它主要影响到治疗设施的关闭、国内流离失所和被迫移民。

Market Overview

The Global Antibody Drug Conjugates Market size reached US$ 5,032.8 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 16,594.6 million by 2030. The market is exhibiting at a CAGR of 16.6% during the forecast period (2023-2030).

The global antibody drug conjugates market is driven by factors such as the increasing prevalence of cancer, growing investments in research and developments related to cancer, increasing innovative and targeted treatment options for cancer, and advancements in antibody engineering and conjugation technologies.

Market Dynamics

Increasing Prevalence Of Cancer

The increasing prevalence of cancer is a major factor driving the market share during the forecast period. The increasing incidence of cancer globally has resulted in a larger patient population in need of effective treatments. ADCs offer a targeted approach to cancer therapy by delivering cytotoxic payloads directly to cancer cells, potentially improving treatment outcomes. As the number of cancer patients rises, there is a greater demand for innovative and effective therapies like ADCs.

Traditional cancer treatments, such as chemotherapy, radiation therapy, and surgery, have limitations in terms of efficacy and tolerability. ADCs have demonstrated enhanced efficacy by combining the specificity of monoclonal antibodies with the cytotoxic effects of chemotherapy drugs. They can selectively target cancer cells while sparing healthy cells, leading to improved treatment outcomes. The increasing prevalence of cancer necessitates the development and adoption of more effective treatments, positioning ADCs as a promising solution.

High Production Cost & Side Effects of ADCs

High production costs and side effects associated with antibody drug conjugations is a major factor hampering the market share during the forecast period. The development and manufacturing of ADCs involve complex processes, including the production of monoclonal antibodies, conjugation chemistry, purification, and formulation. These processes require specialized infrastructure, expertise, and resources, resulting in high production costs.

The high cost of producing ADCs can limit their accessibility and affordability, especially in healthcare systems with budget constraints or regions with limited resources. The cost of ADCs can also be a barrier to reimbursement by healthcare payers, further impacting market share.

ADCs are designed to deliver cytotoxic agents selectively to cancer cells, but they can still cause off-target effects and side effects. Common side effects include hematological toxicity, liver toxicity, immunogenicity, and infusion-related reactions. Side effects and safety concerns can impact patient acceptance, treatment compliance, and market adoption of ADCs, so it is important to reduce side effects and enhance safety profiles.

COVID-19 Impact Analysis

The COVID-19 pandemic has had a significant impact on the antibody drug conjugates market. The global supply chain disruptions caused by the pandemic have affected the production and availability of ADCs. Lockdowns, travel restrictions, and quarantine measures have disrupted logistics and transportation, resulting in delays and shortages in raw materials, reagents, and finished products. The disruptions in the supply chain have impacted the manufacturing capacity, inventory levels, and delivery timelines of ADCs.

The pandemic has also led to the delay or suspension of clinical trials of ADCs. The focus of healthcare systems, clinical trial sponsors, and regulatory agencies has shifted towards addressing the pandemic, leading to delays and disruptions in ongoing clinical trials. Delayed clinical trials can affect the regulatory approval timelines and market entry of ADCs.

Russia-Ukraine Conflict Analysis

The Russia-Ukraine conflict negatively impacted the antibody drug conjugation market. If the conflict escalates and leads to political instability, it can disrupt the global supply chain for pharmaceutical products, including ADCs. Ukraine is a significant player in the production of pharmaceutical ingredients and has a robust pharmaceutical industry.

Any disruptions in the supply chain, such as export restrictions, transportation disruptions, or political instability, could affect the availability of raw materials and components needed for ADC production, potentially leading to supply shortages and impacting the market.

Significant contributions are made by Ukraine and Russia to international cancer clinical trials. The situation in Ukraine will have a variety of effects on performing clinical trials, but it mainly affects the closure of treatment facilities, internal displacement, and forced migration.

Segment Analysis

The global antibody drug conjugates market is segmented based on application, technology, and region.

Based On Application, The Breast Cancer Segment Dominates The Market Share

Based on application, the breast cancer segment dominates the market share of around 48.6% during the forecast period. Breast cancer has a high incidence rate worldwide, making it a significant public health concern. The increasing prevalence of breast cancer contributes to the larger patient population in need of effective treatment options. As a result, there is a strong demand for targeted therapies, such as ADCs, for the treatment of breast cancer.

ADCs offer a targeted treatment approach for breast cancer by selectively delivering cytotoxic payloads to cancer cells expressing specific antigens, such as HER2 or estrogen receptors. This targeted approach enhances treatment efficacy and reduces toxicity compared to traditional chemotherapy. The ability of ADCs to address specific molecular targets in breast cancer makes them a favorable choice for clinicians and patients.

Geographical Analysis

North America Holds The Largest Market Share Due To The Increasing R&D on ADC Products

North America holds the largest market share of about 51.4% during the forecast period due to the increasing R&D on ADC. North America, particularly the United States, has a strong focus on research and development in the pharmaceutical industry. Many leading pharmaceutical companies, biotechnology firms, and academic institutions in North America are actively engaged in ADC research and development.

Competitive Landscape

The major global players in the market include: Takeda Pharmaceutical Company Ltd., Hoffmann-La Roche, Pfizer, AstraZeneca, Gilead Sciences, Seagen, Astellas Pharma, Daiichi Sankyo Company, GlaxoSmithKline, and ADC Therapeutics.

Why Purchase the Report?

To visualize the global antibody drug conjugates market segmentation based on application, technology, and region, and understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of antibody drug conjugates market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as Excel consisting of key products of all the major players.

The global antibody drug conjugates market report would provide approximately 54 tables, 46 figures, and 195 pages.

Target Audience 2023

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Application
3.2. Snippet by Technology
3.3. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Increasing prevalence of cancer
- 4.1.2. Restraints
  - 4.1.2.1. High production cost & side effects of ADCs
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID-19
- 6.1.2. Scenario During COVID-19
- 6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturer's Strategic Initiatives
6.6. Conclusion

7. By Application

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 7.1.2. Market Attractiveness Index, By Application
7.2. Breast cancer*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Blood cancer
7.4. Skin cancer
7.5. Lung cancer
7.6. Ovary cancer
7.7. Others

8. By Technology

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 8.1.2. Market Attractiveness Index, By Technology
8.2. Non-cleavable linker*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Cleavable linker
8.4. Linker less

9. By Region

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 9.1.2. Market Attractiveness Index, By Region
9.2. North America
- 9.2.1. Introduction
- 9.2.2. Key Region-Specific Dynamics
- 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.2.5.1. The U.S.
  - 9.2.5.2. Canada
  - 9.2.5.3. Mexico
9.3. Europe
- 9.3.1. Introduction
- 9.3.2. Key Region-Specific Dynamics
- 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.3.5.1. Germany
  - 9.3.5.2. The UK
  - 9.3.5.3. France
  - 9.3.5.4. Italy
  - 9.3.5.5. Spain
  - 9.3.5.6. Rest of Europe
9.4. South America
- 9.4.1. Introduction
- 9.4.2. Key Region-Specific Dynamics
- 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.4.5.1. Brazil
  - 9.4.5.2. Argentina
  - 9.4.5.3. Rest of South America
9.5. Asia-Pacific
- 9.5.1. Introduction
- 9.5.2. Key Region-Specific Dynamics
- 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.5.5.1. China
  - 9.5.5.2. India
  - 9.5.5.3. Japan
  - 9.5.5.4. Australia
  - 9.5.5.5. Rest of Asia-Pacific
9.6. Middle East and Africa
- 9.6.1. Introduction
- 9.6.2. Key Region-Specific Dynamics
- 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology

10. Competitive Landscape

10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis

11. Company Profiles

11.1. Takeda Pharmaceutical Company Ltd.*
- 11.1.1. Company Overview
- 11.1.2. Product Portfolio and Description
- 11.1.3. Financial Overview
- 11.1.4. Key Developments
11.2. Hoffmann-La Roche Ltd.
11.3. Pfizer Inc.
11.4. AstraZeneca
11.5. Gilead Sciences Inc.
11.6. Seagen Inc.
11.7. Astellas Pharma
11.8. Daiichi Sankyo Company Ltd.
11.9. GlaxoSmithKline Plc
11.10. ADC Therapeutics

LIST NOT EXHAUSTIVE